Supernus Pharmaceuticals SUPN Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's change in AP?
- Supernus Pharmaceuticals (SUPN) reported change in AP of $49K in Q1 2026.
- How has Supernus Pharmaceuticals's change in AP changed year-over-year?
- Supernus Pharmaceuticals's change in AP decreased by 98.8% year-over-year, from $3.94M to $49K.
- What is the long-term trend for Supernus Pharmaceuticals's change in AP?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's change in AP has grown at a 7.8% compound annual growth rate (CAGR), from $18.18M to -$24.57M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.